IND-SWIFT LABORATORIES LTD. SHARE PRICE [LIVE]

  
NSE: INDSWFTLAB
64.25
BSE: 532305
64.45
To view real time prices Login to your account
OPEN YOUR FREE DEMAT ACCOUNT AND START TRADING SEAMLESSLY
Already an existing customer? - Login Now!
NSE
BSE Click here to view BSE data
Live Chart
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
Open:
High:
Low:
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
P/E:
Div yield:

Fundamental analysis

Quality

Valuation
0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Stock
-12.27%
Sector
-6.39%
Sensex
8.59%
Underperformed both Sector by -5.88% and Sensex by -20.86%
IndustryPharma
MARKET CAP (Micro Cap Stock)Rs 378 Cr
PE (TTM) -381.11
DIVIDEND YIELD 0.00%
PE Ratio-381.11
Price to Book Value0.59
EV to EBIT19.72
EV to EBITDA6.39
EV to Capital Employed0.83
EV to Sales1.12
PEG Ratio0.00
Dividend YieldNA
ROCE (Latest)4.20%
ROE (Latest)-0.03%
NameSep 22Jun 22
Promoters (Change:-0.00) 42%42%
FIIs (Change:-0.00) 0%0%
Mutual Funds (Change:0.00) 0%0%
Insurance Companies (Change:0.00) 0%0%
Other DIIs (Change:0.00) 19.49%19.49%
Non Institution (Change:-0.00) 38.5%38.5%

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000

in IND-SWIFT LABORATORIES LTD.

Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %

INDSWFTLAB News

Frequently Asked Questions

What is the Share price of IND-SWIFT LABORATORIES LTD. (INDSWFTLAB)?

IND-SWIFT LABORATORIES LTD. (INDSWFTLAB) share price as of December 5, 2022, on NSE is Rs 64.25 (NSE) and Rs 64.45 (BSE) on BSE.

Can I buy IND-SWIFT LABORATORIES LTD. (INDSWFTLAB) shares?

Yes, You can buy IND-SWIFT LABORATORIES LTD. (INDSWFTLAB) shares by opening a Demat account with Angel One.

How do I buy IND-SWIFT LABORATORIES LTD. (INDSWFTLAB) from Angel One?

IND-SWIFT LABORATORIES LTD. (INDSWFTLAB) share can be brought through the following modes:
  1. Direct investment: You can buy IND-SWIFT LABORATORIES LTD. (INDSWFTLAB) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to IND-SWIFT LABORATORIES LTD. (INDSWFTLAB) shares.

In which sector do IND-SWIFT LABORATORIES LTD. (INDSWFTLAB) belong?

IND-SWIFT LABORATORIES LTD. (INDSWFTLAB) belongs to Pharma.

About INDSWFTLAB

Today's live share price for IND-SWIFT LABORATORIES LTD. is NSE: ₹ 64.25, BSE: ₹ 64.45 with a current market capitalization of .

Ind-Swift Laboratories Ltd is a part of the Ind-swift Group and is based at Chandigarh, India. The company manufactures and sells active pharmaceutical ingredients (API). Their product pipeline consists of 25 products, which includes drugs, which include Clarithromycin (Macrolide antibiotic), Atorvastatin (anticholestrol), Fexofenadine (antihistamine), Clopidogrel (anticholestrol), Nitazoxanide (antidiarrheal), Pioglitazone (antidiabetic), Letrozole and Anastrozole (anticancer), Venlafaxine (antidepressants) and Quetipine and Aripirazole (antipsychotic). The company has one subsidiary namely, Ind-Swift Laboratories Inc in USA. Ind-Swift Laboratories Ltd was incorporated in the year 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation. Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company. The company commenced their production in the year 1997. Over a short period, the company has emerged as a respectable and dependable supplier of Bulk-Actives in more than 40 countries. In the year 1997, the company went public and concentrated on the manufacture of Active Pharmaceutical Ingredients (API). In the year 1998-99, they launched two molecules, Clarithromycin and Roxithromycin. Their in-house R&D developed Clarithromycin Granules for the first time in India. In the year 2000, the company developed a new drug namely, Astrovastatin. In addition, they entered into an agreement with eight international pharmaceutical companies to source their requirements for Clarithromycin Fexofenadine Roxithromycin and Candesartan from the company. During the year 2003-04, the company increased the production capacity of bulk drugs/ intermediates from 81.18 TPA to 120 TPA. In addition, they commissioned the granulation facility as per CGMP standards. They launched four new products namely, Acamprosate (alcohol abstinence), Ezetimibe (anti-hyperlipidemic), Anastrazole (oncology) and Nitazoxanide (anti-diarroheal). In January 2, 2004, the company incorporated a wholly owned subsidiary, namely Ind-Swift Laboratories Inc in USA to strengthen the company's presence in contract research and manufacturing services. In June 2004, the subsidiary company commenced their operations. During the year 2004-05, the company expanded the production capacity of bulk drugs/ intermediates from 120 TPA to 150 TPA. They commissioned waste heat recovery unit to reduce energy costs. They opened and office in China to facilitate the import of raw materials. The company introduced five new products in the market. During the year 2005-06, the company completed and commissioned their new plant at Samba in Jammu & Kashmir to manufacture products for the domestic markets. Also, they set up a new state of the art Research & Development center at Mohali, Punjab with an investment of USD 5 million. They increased the production capacity of bulk drugs/ intermediates by 87.03 TPA to 237.03 TPA. During the year, the company launched new products namely, Letrozole, Anastrozole (Anti-Cancer) Venlafaxine (Anti-Depressants) Lavofloxacin (Anti-Biotic) Quetipine & Aripirazole (Anti-Pshychotic) in the market. They entered into a joint venture with Farayand Chemi Hakim Co, a private joint stock company registered under the law of Iran to focus on the marketing of the products in Middle East & Iran. During the year 2006-07, the company expanded the production capacity of bulk drugs/ intermediates by 18.85 TPA to 255.88 TPA. In April 2006, the company inaugurated their new manufacturing facilities at Baddi in Himachal Pradesh to manufacture tablets, injectibles and liquids. During the year 2007-08, the company entered into the field of Phytochemicals, where, the company has put to operation a new manufacturing facility to manufacture mint-based products. They increased the production capacity of bulk drugs/ intermediates by 162.30 TPA to 418.18 TPA.

Read more

Enjoy Zero Brokerage on Equity Delivery

Join our 1 Cr+ happy customers